Glenmark Pharmaceuticals has launched an epinephrine injection, which is the first FDA-approved generic version of Auvi-Q, according to a report by Drug Store News. The epinephrine injection, also known as epinephrine injection, USP, is a prescription medication used to treat life-threatening allergic reactions, including anaphylaxis.
The medication is available in a pre-filled syringe and is administered via intramuscular injection, typically in the middle of the outer thigh. It is designed to provide fast and effective relief from severe allergic reactions, which can be caused by a range of allergens, including food, insect stings, and latex.
The launch of the epinephrine injection by Glenmark is significant, as it provides patients with a more affordable alternative to branded products. The list price of Glenmark’s epinephrine injection is expected to be lower than that of Auvi-Q, making it a more accessible option for patients who require this life-saving medication.
Glenmark’s epinephrine injection has been approved by the FDA in two doses: 0.3mg and 0.15mg. The 0.3mg dose is intended for patients who weigh 30kg or more, while the 0.15mg dose is intended for patients who weigh between 15kg and 30kg. The medication is available in a carton of two auto-injectors, each containing a single dose of epinephrine.
The launch of Glenmark’s epinephrine injection is an important development for patients who are at risk of anaphylaxis. Anaphylaxis is a severe and potentially life-threatening allergic reaction that requires immediate medical attention. Symptoms of anaphylaxis can include difficulty breathing, rapid heartbeat, and a drop in blood pressure. If left untreated, anaphylaxis can lead to serious health consequences, including death.
Glenmark’s epinephrine injection provides patients with a reliable and effective treatment option for anaphylaxis. The medication has undergone rigorous testing and has been shown to be safe and effective in clinical trials. With its launch, Glenmark is helping to expand access to this critical medication, making it more widely available to patients who need it.
Overall, the launch of Glenmark’s epinephrine injection is a significant development in the treatment of anaphylaxis. The medication provides patients with a fast and effective treatment option for severe allergic reactions, and its availability is expected to improve health outcomes for patients who are at risk of anaphylaxis.